1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H1 2020, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.
Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 15, 42, 22 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 13 and 12 molecules, respectively.
Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Zika Virus Infections - Overview
- Zika Virus Infections - Therapeutics Development
- Zika Virus Infections - Therapeutics Assessment
- Zika Virus Infections - Companies Involved in Therapeutics Development
- Zika Virus Infections - Drug Profiles
- Zika Virus Infections - Dormant Projects
- Zika Virus Infections - Discontinued Products
- Zika Virus Infections - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Zika Virus Infections, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Products under Development by Companies, H1 2020 (Contd..3), H1 2020
- Products under Development by Companies, H1 2020 (Contd..4), H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Zika Virus Infections - Pipeline by Activirosomes Ltd, H1 2020
- Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, H1 2020
- Zika Virus Infections - Pipeline by AIM ImmunoTech Inc, H1 2020
- Zika Virus Infections - Pipeline by Akshaya Bio Inc, H1 2020
- Zika Virus Infections - Pipeline by Aravive Inc, H1 2020
- Zika Virus Infections - Pipeline by Bharat Biotech Ltd, H1 2020
- Zika Virus Infections - Pipeline by Biken Co Ltd, H1 2020
- Zika Virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2020
- Zika Virus Infections - Pipeline by BioNet- Asia Co Ltd, H1 2020
- Zika Virus Infections - Pipeline by Biotron Ltd, H1 2020
- Zika Virus Infections - Pipeline by BravoVax Co Ltd, H1 2020
- Zika Virus Infections - Pipeline by CanSino Biologics Inc, H1 2020
- Zika Virus Infections - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
- Zika Virus Infections - Pipeline by Cidara Therapeutics Inc, H1 2020
- Zika Virus Infections - Pipeline by Ciloa, H1 2020
- Zika Virus Infections - Pipeline by Clayton Biotechnologies Inc, H1 2020
- Zika Virus Infections - Pipeline by Cocrystal Pharma Inc, H1 2020
- Zika Virus Infections - Pipeline by Codagenix Inc, H1 2020
- Zika Virus Infections - Pipeline by Emergent BioSolutions Inc, H1 2020
- Zika Virus Infections - Pipeline by Emergex Vaccines Ltd, H1 2020
- Zika Virus Infections - Pipeline by Ennaid Therapeutics LLC, H1 2020
- Zika Virus Infections - Pipeline by Enyo Pharma SA, H1 2020
- Zika Virus Infections - Pipeline by Etubics Corp, H1 2020
- Zika Virus Infections - Pipeline by Excivion Ltd, H1 2020
- Zika Virus Infections - Pipeline by Expres2ion Biotechnologies ApS, H1 2020
- Zika Virus Infections - Pipeline by Future Medicine Co Ltd, H1 2020
- Zika Virus Infections - Pipeline by GeneOne Life Science Inc, H1 2020
- Zika Virus Infections - Pipeline by GeoVax Labs Inc, H1 2020
- Zika Virus Infections - Pipeline by Greffex Inc, H1 2020
- Zika Virus Infections - Pipeline by GT Biopharma Inc, H1 2020
- Zika Virus Infections - Pipeline by Hawaii Biotech Inc, H1 2020
- Zika Virus Infections - Pipeline by Heat Biologics Inc, H1 2020
- Zika Virus Infections - Pipeline by HSRx Group, H1 2020
- Zika Virus Infections - Pipeline by Humabs BioMed SA, H1 2020
- Zika Virus Infections - Pipeline by IDBiologics Inc, H1 2020
- Zika Virus Infections - Pipeline by Immunomodulation Inc, H1 2020
- Zika Virus Infections - Pipeline by Imutex Ltd, H1 2020
- Zika Virus Infections - Pipeline by IMV Inc, H1 2020
- Zika Virus Infections - Pipeline by Indian Immunologicals Ltd, H1 2020
- Zika Virus Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2020
- Zika Virus Infections - Pipeline by Johnson & Johnson, H1 2020
- Zika Virus Infections - Pipeline by Kamada Ltd, H1 2020
- Zika Virus Infections - Pipeline by KM Biologics Co Ltd, H1 2020
- Zika Virus Infections - Pipeline by Macrophage Therapeutics Inc, H1 2020
- Zika Virus Infections - Pipeline by Medigen Inc, H1 2020
- Zika Virus Infections - Pipeline by Microbiotix Inc, H1 2020
- Zika Virus Infections - Pipeline by Moderna Inc, H1 2020
- Zika Virus Infections - Pipeline by NanoViricides Inc, H1 2020
- Zika Virus Infections - Pipeline by Novalex Therapeutics Inc, H1 2020
- Zika Virus Infections - Pipeline by Orgenesis Inc, H1 2020
- Zika Virus Infections - Pipeline by Ostrich Pharma USA Inc, H1 2020
- Zika Virus Infections - Pipeline by Palisades Therapeutics, H1 2020
- Zika Virus Infections - Pipeline by Pharos Biologicals LLC, H1 2020
- Zika Virus Infections - Pipeline by Phoenix Biotechnology Inc, H1 2020
- Zika Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H1 2020
- Zika Virus Infections - Pipeline by Precision Virologics Inc, H1 2020
- Zika Virus Infections - Pipeline by ProtInhi BV, H1 2020
- Zika Virus Infections - Pipeline by Replikins Ltd, H1 2020
- Zika Virus Infections - Pipeline by Riboscience LLC, H1 2020
- Zika Virus Infections - Pipeline by Sanofi, H1 2020
- Zika Virus Infections - Pipeline by Sementis Ltd, H1 2020
- Zika Virus Infections - Pipeline by Spotlight Innovation Inc, H1 2020
- Zika Virus Infections - Pipeline by Stabilitech Biopharma Ltd, H1 2020
- Zika Virus Infections - Pipeline by Starpharma Holdings Ltd, H1 2020
- Zika Virus Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
- Zika Virus Infections - Pipeline by TechnoVax Inc, H1 2020
- Zika Virus Infections - Pipeline by Themis Bioscience GmbH, H1 2020
- Zika Virus Infections - Pipeline by Theravectys SA, H1 2020
- Zika Virus Infections - Pipeline by Tiba Biotech LLC, H1 2020
- Zika Virus Infections - Pipeline by Tychan Pte Ltd, H1 2020
- Zika Virus Infections - Pipeline by Valneva SE, H1 2020
- Zika Virus Infections - Pipeline by VBI Vaccines Inc, H1 2020
- Zika Virus Infections - Pipeline by VenatoRx Pharmaceuticals Inc, H1 2020
- Zika Virus Infections - Pipeline by Virocovax, H1 2020
- Zika Virus Infections - Pipeline by Xenothera SAS, H1 2020
- Zika Virus Infections - Dormant Projects, H1 2020
- Zika Virus Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Zika Virus Infections - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Zika Virus Infections, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Activirosomes Ltd
- Acuitas Therapeutics Inc
- AIM ImmunoTech Inc
- Akshaya Bio Inc
- Aravive Inc
- Bharat Biotech Ltd
- Biken Co Ltd
- BioCryst Pharmaceuticals Inc
- BioNet- Asia Co Ltd
- Biotron Ltd
- BravoVax Co Ltd
- CanSino Biologics Inc
- Chugai Pharmaceutical Co Ltd
- Cidara Therapeutics Inc
- Ciloa
- Clayton Biotechnologies Inc
- Cocrystal Pharma Inc
- Codagenix Inc
- Emergent BioSolutions Inc
- Emergex Vaccines Ltd
- Ennaid Therapeutics LLC
- Enyo Pharma SA
- Etubics Corp
- Excivion Ltd
- Expres2ion Biotechnologies ApS
- Future Medicine Co Ltd
- GeneOne Life Science Inc
- GeoVax Labs Inc
- Greffex Inc
- GT Biopharma Inc
- Hawaii Biotech Inc
- Heat Biologics Inc
- HSRx Group
- Humabs BioMed SA
- IDBiologics Inc
- Immunomodulation Inc
- Imutex Ltd
- IMV Inc
- Indian Immunologicals Ltd
- Inovio Pharmaceuticals Inc
- Johnson & Johnson
- Kamada Ltd
- KM Biologics Co Ltd
- Macrophage Therapeutics Inc
- Medigen Inc
- Microbiotix Inc
- Moderna Inc
- NanoViricides Inc
- Novalex Therapeutics Inc
- Orgenesis Inc
- Ostrich Pharma USA Inc
- Palisades Therapeutics
- Pharos Biologicals LLC
- Phoenix Biotechnology Inc
- Plex Pharmaceuticals Inc
- Precision Virologics Inc
- ProtInhi BV
- Replikins Ltd
- Riboscience LLC
- Sanofi
- Sementis Ltd
- Spotlight Innovation Inc
- Stabilitech Biopharma Ltd
- Starpharma Holdings Ltd
- Takeda Pharmaceutical Co Ltd
- TechnoVax Inc
- Themis Bioscience GmbH
- Theravectys SA
- Tiba Biotech LLC
- Tychan Pte Ltd
- Valneva SE
- VBI Vaccines Inc
- VenatoRx Pharmaceuticals Inc
- Virocovax
- Xenothera SAS
